The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca in children for the first time.
The new mid-stage trial will determine whether the vaccine is effective for people between the ages of six and 17, according to a statement from the university on Saturday.Up to 240 subjects will receive the vaccine, while the rest will receive a controlled drug.
The two-dose Oxford-AstraZeneca vaccine has been hailed as a “vaccine for the world” because it is cheaper and easier to distribute than some rivals. AstraZeneca has a target to produce three billion doses this year and aims to produce more than 200 million doses per month by April.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: